FDA Approves Second Generic Abortion Pill Amidst Safety Review and Political Backlash
The FDA approved a second generic abortion pill, mifepristone, by Evita Solutions, amidst an ongoing safety review announced by Health Secretary Robert F. Kennedy Jr. and conservative opposition.
Overview
The FDA has approved a new generic version of the abortion pill mifepristone, allowing Evita Solutions to market the medication for terminating pregnancies up to 10 weeks.
This marks the second generic mifepristone approval, following GenBioPro's in 2019, making the drug more widely available alongside the original brand-name version.
The approval comes despite an ongoing FDA safety review of mifepristone, which Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary committed to.
Mifepristone, typically used with misoprostol, is central to medication abortions, which constitute approximately two-thirds of all abortions in the United States.
While the FDA deems the pill safe, its access remains restricted in many states due to existing abortion bans and ongoing legal challenges.
Analysis
Center-leaning sources frame the FDA's generic abortion pill approval as a standard regulatory action, emphasizing the drug's established safety and effectiveness. They highlight conservative "outrage" and "pushback" against what is presented as a "rote process," while underscoring the medical community's support for access and the drug's role in expanding care.